- Innovative clinic establishes new patient-first model for Colombia with the benefits of complementary professional medical services in a single, integrated care environment
- Clinic features contemporary design across four expansive floors, within 600 metres of Bogota’s largest transit hub, and in the city’s prime medical services district
- 15,000 sq. ft clinic offers comprehensive suite of health and medical services in alignment with insurance company partners
- Zerenia launch follows the successful growth of Company’s Ilans neurological clinics
- Zerenia branded clinic in keeping with Khiron’s patient acquisition strategy as Company prepares for cannabis prescriptions in Colombia
Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV:KHRN, OTCQB:KHRNF, Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced the opening of Zerenia, a fully integrated medical care clinic designed to meet patient health and well-being. Operating in a 15,000 sq. ft facility in Bogota’s prime medical services district, the clinic increases Khiron’s clinical capacity by 75% and forms part of the Company’s patient acquisition strategy as it prepares for the issue of cannabis prescription in Colombia.
Zerenia Integrated Medical Clinic
Health professionals at Khirons newly opened Zerenia integrated medical clinic
Zerenia offers a person-centered integrated care model, with the concept of integrative medicine combining traditional and complementary medicine, and with evidence-based treatments and high professional practices. Services are delivered across multiple clinical units include: Pain management, mental health, surgical, neurology and dentistry, supported by rehabilitation, complementary medicine and diagnostic technology, involving programs for managing multiple symptoms in different pathologies. Prominently located in Bogota’s city centre, Zerenia builds on the integration and growth of the Company’s wholly-owned Ilans neurological clinics and its over 60 physicians, and is staffed by a team of health professionals and clinical leaders representing different specialties.
Phase one of the 15,000 sq. ft clinic is open for treatments and phase two will be ready to receive patients in March 2020.
“We are excited to be opening Zerenia in Bogota, a busy city of more than 10 million people and a population increasingly demanding convenient, one-stop access to medical care of the highest professional standards. In a state of the art clinic, our physicians and health care professionals will consult with patients and offer appropriate treatment therapies.” Comments Martha Edith Oyuela, Khiron Health Vice President. “For the first time patients will have access to an array of integrated professional, patient-centred options.”
“Our strategy in launching Zerenia is to meet a very clear market need to treat the whole patient in one professional environment. With the success of our Ilans clinics, and the growing movement towards integrated medical care, we are leading the market in bringing this concept to Colombia. This strategy further expands our reach to bring patients into the Khiron network, including those that are well suited for cannabis therapies.” Adds Khiron CEO and Director Alvaro Torres.
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. The company delivers best in class regulatory compliance, has the first approved set of CBD cosmetic products on shelf in Colombia, and is currently facilitating testing to meet and surpass all license requirements for commercial cannabis derived products.
With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.
Visit Khiron online at www.khiron.ca and on Instagram @khironlife
This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
United States Disclaimer
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.